Details of the SBP

General Information of Synthetic Binding Protein (SBP) (ID: SBP000292)
SBP Name	Macrocyclic peptide Lanreotide
Synonyms	Angiopeptin; Somatuline; Lanreotida; BIM 23014; BIM 23014C; Dermopeptin; Ipstyl; ITM-014; ITM-014T
Molecular Weight	1.1 kDa
Design Method	Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status	Marketed
Sequence Length	8
SBP Sequence	>Macrocyclic peptide Lanreotide [Nal]CY[d-Trp]KVCT
Sequence Description	Cys I and Cys II form disulfide bonds.

Protein Scaffold Information of This SBP
Scaffold ID	PS044 Scaffold Info	[1]
Scaffold Name	Macrocyclic peptide
Scaffold Class	Non-Antibody
Fold Type	Beta-Sheets + Loops

Binding Target(s) of This SBP (BTS)

BTS Name	Details	Mechanism	Application	Affinity	Research Organization	Ref
Somatostatin receptor type 1	BTS Info	Inhibitor	Neuroendocrine tumour [ICD-11: XH8DS0]; Acromegaly or pituitary gigantism [ICD-11: 5A60.0]; Graves ophthalmopathy [ICD-11: 9C82.3]; Pituitary cancer [ICD-11: 2D12.Z]; Pancreatic cancer [ICD-11: 2C10.Z]; Gastrointestinal motility disorders	N.A.	Ipsen Biopharmaceuticals; Stanford University School of Medicine	[1]

Clinical Trial Information of This SBP
NCT00092287	Click to show the Detail
Indication	Malignant Carcinoid Syndrome
Phase	Phase III
Title	Comparison of Lanreotide Autogel? and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
Status	Terminated
Sponsor	Ipsen
NCT00145405	Click to show the Detail
Indication	Acromegaly
Phase	Phase IV
Title	Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
Status	Completed
Sponsor	Odense University Hospital
NCT00149188	Click to show the Detail
Indication	Acromegaly
Phase	Phase IV
Title	Somatuline Autogel: Acromegaly Self/Partner Injection Study
Status	Completed
Sponsor	Ipsen
NCT00210457	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
Status	Completed
Sponsor	Ipsen
NCT00216372	Click to show the Detail
Indication	Intestinal Obstruction; Carcinoma; Peritoneal Neoplasms
Phase	Phase III
Title	Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
Status	Completed
Sponsor	Ipsen
NCT00216398	Click to show the Detail
Indication	Acromegaly
Phase	Phase IV
Title	Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
Status	Completed
Sponsor	Ipsen
NCT00234520	Click to show the Detail
Indication	Acromegaly
Phase	.
Title	A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide
Status	Completed
Sponsor	Ipsen
NCT00234572	Click to show the Detail
Indication	Acromegaly
Phase	Phase II; Phase III
Title	Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
Status	Completed
Sponsor	Ipsen
NCT00288522	Click to show the Detail
Indication	Thyroid-Associated Ophthalmopathy
Phase	Phase II
Title	Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
Status	Terminated
Sponsor	Ipsen
NCT00326469	Click to show the Detail
Indication	Neuroendocrine Tumours
Phase	Phase II
Title	Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
Status	Completed
Sponsor	Ipsen
NCT00353496	Click to show the Detail
Indication	Endocrine Tumors
Phase	Phase III
Title	Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Status	Completed
Sponsor	Ipsen
NCT00383708	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
Status	Completed
Sponsor	Ipsen
NCT00444873	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
Status	Completed
Sponsor	Ipsen
NCT00447499	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status	Completed
Sponsor	Ipsen
NCT00495846	Click to show the Detail
Indication	Advanced Hepatocellular Carcinoma
Phase	Phase II; Phase III
Title	GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma
Status	Completed
Sponsor	Federico II University
NCT00499993	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
Status	Completed
Sponsor	Ipsen
NCT00517491	Click to show the Detail
Indication	Acromegaly
Phase	Phase II
Title	Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
Status	Withdrawn
Sponsor	Ipsen
NCT00543179	Click to show the Detail
Indication	Dumping Syndrome
Phase	Phase IV
Title	Treatment of the Dumping Syndrome With Lanreotide Autogel?
Status	Unknown
Sponsor	Radboud University
NCT00565097	Click to show the Detail
Indication	Polycystic Liver Disease; Hepatomegaly; Liver Diseases; Polycystic Kidney, Autosomal Dominant
Phase	Phase II; Phase III
Title	Lanreotide as Treatment of Polycystic Livers
Status	Completed
Sponsor	Radboud University
NCT00615004	Click to show the Detail
Indication	Acromegaly
Phase	.
Title	Cardiovascular Outcome After Surgery or Somatostatin Analogues
Status	Completed
Sponsor	Federico II University
NCT00627796	Click to show the Detail
Indication	Acromegaly
Phase	Phase IV
Title	Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly
Status	Completed
Sponsor	Federico II University
NCT00630695	Click to show the Detail
Indication	Lymphocele
Phase	Phase III
Title	Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer
Status	Completed
Sponsor	University Hospital, Limoges
NCT00652379	Click to show the Detail
Indication	Acromegaly; Insulin Resistance; Impaired Glucose Tolerance
Phase	Not Applicable
Title	Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
Status	Completed
Sponsor	University of Aarhus
NCT00681187	Click to show the Detail
Indication	Neuroendocrine Tumour With Carcinoid Symptoms
Phase	Phase IV
Title	Somatuline Autogel Preference and Health Economy Study
Status	Completed
Sponsor	Ipsen
NCT00686348	Click to show the Detail
Indication	Acromegaly
Phase	.
Title	Somatuline? Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study
Status	Completed
Sponsor	Ipsen
NCT00690898	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Status	Completed
Sponsor	Ipsen
NCT00701363	Click to show the Detail
Indication	Acromegaly
Phase	Phase IV
Title	Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
Status	Completed
Sponsor	Ipsen
NCT00703079	Click to show the Detail
Indication	Acromegaly
Phase	.
Title	Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly
Status	Completed
Sponsor	Federico II University
NCT00729313	Click to show the Detail
Indication	Digestive Fistulae
Phase	Phase III
Title	Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae
Status	Completed
Sponsor	Ipsen
NCT00747500	Click to show the Detail
Indication	Acromegaly
Phase	.
Title	Non Interventional Post Marketing Programme in Acromegaly
Status	Completed
Sponsor	Ipsen
NCT00747786	Click to show the Detail
Indication	Neuroendocrine Tumors
Phase	.
Title	Non Interventional Post Marketing Programme in Neuroendocrine Tumours
Status	Completed
Sponsor	Ipsen
NCT00771888	Click to show the Detail
Indication	Polycystic Liver Disease; Hepatomegaly; Liver Diseases; Polycystic Kidney; Autosomal Dominant
Phase	Phase II; Phase III
Title	Open-Label Extension of LOCKCYST Trial
Status	Unknown
Sponsor	Radboud University
NCT00774930	Click to show the Detail
Indication	Carcinoid Syndrome
Phase	Phase III
Title	An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Status	Completed
Sponsor	Ipsen
NCT00842348	Click to show the Detail
Indication	Non Functioning Entero-pancreatic Endocrine Tumour
Phase	Phase III
Title	Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour
Status	Completed
Sponsor	Ipsen
NCT00891371	Click to show the Detail
Indication	Diarrhea
Phase	Phase II; Phase III
Title	Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea
Status	Completed
Sponsor	Ipsen
NCT00916916	Click to show the Detail
Indication	Acromegaly
Phase	.
Title	Lanreotide Levels in Acromegaly
Status	Unknown
Sponsor	Cedars-Sinai Medical Center
NCT00993356	Click to show the Detail
Indication	Acromegaly
Phase	Phase II
Title	Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas
Status	Unknown
Sponsor	Shanghai Jiao Tong University School of Medicine
NCT01070758	Click to show the Detail
Indication	Congenital Hyperinsulinism
Phase	Phase IV
Title	Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy
Status	Unknown
Sponsor	Sheba Medical Center
NCT01076803	Click to show the Detail
Indication	Malignant Intestinal Obstruction
Phase	Phase II
Title	Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients
Status	Completed
Sponsor	University Hospital, Ghent
NCT01137682	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Status	Completed
Sponsor	Novartis Pharmaceuticals
NCT01234168	Click to show the Detail
Indication	Neuroendocrine Tumors; Carcinoid Syndrome
Phase	.
Title	A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
Status	Completed
Sponsor	Ipsen
NCT01313273	Click to show the Detail
Indication	Prostate Cancer
Phase	Phase III
Title	Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
Status	Terminated
Sponsor	Ipsen
NCT01315795	Click to show the Detail
Indication	Polycystic Liver Disease
Phase	Phase II; Phase III
Title	Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease
Status	Completed
Sponsor	Universitaire Ziekenhuizen Leuven
NCT01333384	Click to show the Detail
Indication	Acromegaly
Phase	.
Title	Study in Polish Acromegalic Patients Treated With Somatuline Autogel
Status	Completed
Sponsor	Ipsen
NCT01354405	Click to show the Detail
Indication	Polycystic Liver Disease
Phase	.
Title	Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)
Status	Completed
Sponsor	Radboud University
NCT01372007	Click to show the Detail
Indication	Rectal Carcinoma
Phase	Phase III
Title	Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma
Status	Completed
Sponsor	University Hospital, Ghent
NCT01471405	Click to show the Detail
Indication	Acromegaly
Phase	.
Title	One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma
Status	Completed
Sponsor	Ipsen
NCT01538966	Click to show the Detail
Indication	Acromegaly
Phase	Not Applicable
Title	Acromegaly Combination Treatment Study
Status	Recruiting
Sponsor	Cedars-Sinai Medical Center
NCT01616927	Click to show the Detail
Indication	Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase	Phase III
Title	Study of Lanreotide to Treat Polycystic Kidney Disease
Status	Unknown
Sponsor	University Medical Center Groningen
NCT01731925	Click to show the Detail
Indication	Carcinoid Tumors
Phase	Phase II
Title	A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
Status	Unknown
Sponsor	GERCOR-Multidisciplinary Oncology Cooperative Group
NCT01840449	Click to show the Detail
Indication	Acromegaly; Neuroendocrine Tumours
Phase	.
Title	Somatuline Predictive Factors in Acromegaly and NET
Status	Completed
Sponsor	Ipsen
NCT01861717	Click to show the Detail
Indication	Acromegaly
Phase	Phase IV
Title	A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
Status	Terminated
Sponsor	John Wayne Cancer Institute
NCT01923649	Click to show the Detail
Indication	Dumping Syndrome
Phase	Phase II
Title	SOMATULINE Autogel 90 mg IN DUMPING SYNDROME
Status	Unknown
Sponsor	Universitaire Ziekenhuizen Leuven
NCT02020499	Click to show the Detail
Indication	Acromegaly
Phase	.
Title	Predictive Factors Study
Status	Terminated
Sponsor	Ipsen
NCT02054637	Click to show the Detail
Indication	Acid Reflux Esophagitis; Non-acid Reflux Esophagitis
Phase	Phase II
Title	Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy
Status	Unknown
Sponsor	Universitair Ziekenhuis Brussel
NCT02075606	Click to show the Detail
Indication	NeuroEndocrine Tumours
Phase	Phase IV
Title	Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
Status	Completed
Sponsor	Ipsen
NCT02127437	Click to show the Detail
Indication	Autosomal Dominant Polycystic Kidney Disease (ADPKD
Phase	Phase III
Title	Lanreotide In Polycystic Kidney Disease Study
Status	Completed
Sponsor	Assistance Publique-H?pitaux de Paris
NCT02231762	Click to show the Detail
Indication	Gastroenteropancreatic Neuroendocrine Tumors
Phase	Phase II
Title	Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
Status	Completed
Sponsor	Ipsen
NCT02275338	Click to show the Detail
Indication	Intestinal Obstruction
Phase	Phase II
Title	Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction
Status	Completed
Sponsor	Ipsen
NCT02288377	Click to show the Detail
Indication	Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours
Phase	Phase II; Phase III
Title	A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
Status	Completed
Sponsor	Federation Francophone de Cancerologie Digestive
NCT02351128	Click to show the Detail
Indication	Carcinoma, Merkel Cell
Phase	Phase II
Title	Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues
Status	Completed
Sponsor	University Hospital, Grenoble
NCT02354768	Click to show the Detail
Indication	High Output Stoma
Phase	Phase III
Title	Evaluation of Lanreotide Efficacity in High Output Stoma: a Multicentric Randomized Study
Status	Terminated
Sponsor	University Hospital, Strasbourg, France
NCT02365584	Click to show the Detail
Indication	Intestinal Obstruction
Phase	Phase II
Title	Quality of Life in Patients With Inoperable Malignant Bowel Obstruction
Status	Terminated
Sponsor	Ipsen
NCT02396953	Click to show the Detail
Indication	Acromegaly
Phase	Phase I; Phase II
Title	Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
Status	Completed
Sponsor	Ipsen
NCT02396966	Click to show the Detail
Indication	Acromegaly
Phase	.
Title	Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel? Treatment.
Status	Completed
Sponsor	Ipsen
NCT02493517	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	Efficacy and Safety of Lanreotide Autogel? 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
Status	Completed
Sponsor	Ipsen
NCT02651987	Click to show the Detail
Indication	Pancreatic Tumours; Midgut Neuroendocrine Tumours
Phase	Phase II
Title	Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel? 120 mg
Status	Completed
Sponsor	Ipsen
NCT02683941	Click to show the Detail
Indication	Neuroendocrine Tumors in Lung
Phase	Phase III
Title	Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors
Status	Completed
Sponsor	Ipsen
NCT02685709	Click to show the Detail
Indication	Acromegaly
Phase	Phase III
Title	Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
Status	Active, not recruiting
Sponsor	Chiasma Inc
NCT02698384	Click to show the Detail
Indication	Acromegaly
Phase	.
Title	Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg
Status	Terminated
Sponsor	Ipsen
NCT02698410	Click to show the Detail
Indication	Neuroendocrine Tumours
Phase	Phase II
Title	Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
Status	Completed
Sponsor	Ipsen
NCT02730104	Click to show the Detail
Indication	Gastroenteropancreatic Neuroendocrine Tumors
Phase	.
Title	Community-based Neuroendocrine Tumor (NET) Research Study
Status	Completed
Sponsor	Ipsen
NCT02788578	Click to show the Detail
Indication	Neuroendocrine Tumours
Phase	.
Title	A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel? for Neuroendocrine Tumours
Status	Terminated
Sponsor	Ipsen
NCT02795858	Click to show the Detail
Indication	Carcinoid Tumors
Phase	Phase II
Title	A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Status	Active, not recruiting
Sponsor	Dana-Farber Cancer Institute
NCT02807233	Click to show the Detail
Indication	Acromegaly
Phase	.
Title	Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects
Status	Completed
Sponsor	Ipsen
NCT02823691	Click to show the Detail
Indication	Neuroendocrine Tumors
Phase	Phase I
Title	The MetNET-2 Trial
Status	Active, not recruiting
Sponsor	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NCT02859064	Click to show the Detail
Indication	Neuroendocrine Tumors; Gastrointestinal Neoplasms; Carcinoid Tumors
Phase	Phase II
Title	Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
Status	Active, not recruiting
Sponsor	SCRI Development Innovations, LLC
NCT02973204	Click to show the Detail
Indication	Carcinoma, Hepatocellular; Neuroendocrine Tumors
Phase	.
Title	Circulating Tumor Cells and Tumor DNA in HCC and NET
Status	Completed
Sponsor	University of Aarhus
NCT03012594	Click to show the Detail
Indication	Gastrointestinal Motility Disorder; Intestinal Disease
Phase	Phase II
Title	Lanreotide in the Treatment of Small Bowel Motility Disorders
Status	Completed
Sponsor	Northwell Health
NCT03017690	Click to show the Detail
Indication	Gastroenteropancreatic Neuroendocrine Tumor
Phase	.
Title	Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Status	Completed
Sponsor	Ipsen
NCT03043664	Click to show the Detail
Indication	Gastroenteropancreatic Neuroendocrine Tumors
Phase	Phase I; Phase II
Title	Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
Status	Active, not recruiting
Sponsor	Duke University
NCT03083210	Click to show the Detail
Indication	Neuroendocrine Tumors
Phase	Phase IV
Title	Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET
Status	Unknown
Sponsor	Samsung Medical Center
NCT03112694	Click to show the Detail
Indication	Neuroendocrine Tumors
Phase	.
Title	Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors
Status	Completed
Sponsor	Ipsen
NCT03174353	Click to show the Detail
Indication	Pancreatic Leak; Pancreatic Fistula; Pancreaticoduodenal; Fistula; Pancreatectomy; Hyperglycemia
Phase	Phase II
Title	A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Status	Active, not recruiting
Sponsor	University of Washington
NCT03289741	Click to show the Detail
Indication	Neuroendocrine Tumors
Phase	Phase IV
Title	A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
Status	Active, not recruiting
Sponsor	Memorial Sloan Kettering Cancer Center
NCT03439709	Click to show the Detail
Indication	Acromegaly Due to Pituitary Adenoma
Phase	Phase III
Title	Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma
Status	Not Recruiting
Sponsor	Samsung Medical Center
NCT03562091	Click to show the Detail
Indication	Neuroendocrine Tumors
Phase	.
Title	Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel
Status	Completed
Sponsor	Ipsen
NCT03895463	Click to show the Detail
Indication	Neuroendocrine Tumors
Phase	.
Title	Study to Assess the Use of Lanreotide Autogel? 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice
Status	Withdrawn
Sponsor	Ipsen
NCT03946527	Click to show the Detail
Indication	Paraganglioma; Pheochromocytoma
Phase	Phase II
Title	LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)
Status	Not Recruiting
Sponsor	Antonio Fojo
NCT03947762	Click to show the Detail
Indication	Pancreatic Neuroendocrine Tumor
Phase	.
Title	Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.
Status	Terminated
Sponsor	Ipsen
NCT04003519	Click to show the Detail
Indication	Acromegaly
Phase	.
Title	Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly
Status	Withdrawn
Sponsor	Ipsen
NCT04065165	Click to show the Detail
Indication	Small Intestinal NET; Carcinoid Heart Disease
Phase	Phase III
Title	Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome
Status	Withdrawn
Sponsor	European Organisation for Research and Treatment of Cancer-EORTC
NCT04198402	Click to show the Detail
Indication	Digestive Neuroendocrine Tumor; Fecal Microbiota; Bacterial Signature
Phase	.
Title	Microbiotic Analysis in Digestive Endocrine Tumors
Status	Not Recruiting
Sponsor	Assistance Publique-Hopitaux de Paris
NCT04427787	Click to show the Detail
Indication	Metastatic Well Differentiated Neuroendocrine Neoplasm; Neuroendocrine Tumors
Phase	Phase II
Title	A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
Status	Recruiting
Sponsor	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NCT04649580	Click to show the Detail
Indication	Neuroendocrine Tumours (NET)
Phase	.
Title	United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting
Status	Recruiting
Sponsor	Ipsen
NCT04696042	Click to show the Detail
Indication	Neuroendocrine Tumors
Phase	.
Title	Asian Investigation of Lanreotide Autogel? in the Management of GEP-NETs
Status	Recruiting
Sponsor	Asan Medical Center
NCT04852679	Click to show the Detail
Indication	Gastroenteropancreatic Neuroendocrine Tumor
Phase	Phase III
Title	Study to Assess the Efficacy and Safety of Lanreotide Autogel? in Chinese Participants With GEP-NETs
Status	Recruiting
Sponsor	Ipsen
NCT05048901	Click to show the Detail
Indication	Neuroendocrine Tumors,Gastroenteropancreatic
Phase	Phase I; Phase II
Title	Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
Status	Recruiting
Sponsor	National Health Research Institutes, Taiwan

References

Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study. Oncologist. 2018 Jan;23(1):16-24.